Clinical Trials Logo

Filter by:
NCT ID: NCT05208164 Recruiting - Type 2 Diabetes Clinical Trials

My ESSENCE - A Research Study on Mindfulness for African-Americans With Type 2 Diabetes

E-RCT
Start date: April 1, 2021
Phase: N/A
Study type: Interventional

The proposed research and training will allow Dr. Alana Biggers to obtain critical research skills and study a mindfulness meditation program designed to improve sleep and reduce stress in African-American adults with diabetes. If effective, this program may reduce the risk of cardiovascular disease among African-Americans with type 2 diabetes who are at high risk of cardiovascular disease.

NCT ID: NCT05213793 Recruiting - Stroke Clinical Trials

Multi-delay Arterial Spin Labeling Application in Acute Ischemic Stroke

Start date: April 1, 2021
Phase:
Study type: Observational

This study explores the value of the non-invasive quantitative evaluation system for cerebral blood flow perfusion function in the diagnosis of stroke. Compared with traditional perfusion techniques, multi-delay arterial spin labeling (ASL) is validated to determine the accuracy of perfusion level, ischemic penumbra and other indexes in patients with acute ischemic stroke. The relationship between perfusion levels of mD-ASL parameters and clinical outcome is also studied.

NCT ID: NCT05227495 Recruiting - Virtual Reality Clinical Trials

Effects of the Fully Immersive Leisure-based Virtual Reality Cognitive Training for Community-dwelling Elderly

Start date: April 1, 2021
Phase: N/A
Study type: Interventional

This study aims to (1) determine the feasibility and usability of immersive leisure-based VR cognitive training; (2) identify the intervention effects of immersive leisure-based VR cognitive training on cognitive function, daily function, and quality of life for elderly with community-dwelling elderly

NCT ID: NCT05237817 Recruiting - Stroke Clinical Trials

Association Between Stroke and Adrenal Incidentalomas

ABSAI
Start date: April 1, 2021
Phase:
Study type: Observational [Patient Registry]

Adrenal incidentalomas (AIs) are commonly encountered in transsection imaging which purpose not for suspected adrenal disease. However, part of AIs in patients is associated with Stroke. Stroke is a diseases which could cause of disability and death worldwide. In clinical practice, detailed information about the association between stroke and AIs is not available. In this study, the investigators aimed to investigate the risk for disability and death in the large group of stroke patients with AIs.

NCT ID: NCT05239754 Recruiting - Fathers Clinical Trials

Fresno FAWDB FIRE Program Evaluation

Start date: April 1, 2021
Phase: N/A
Study type: Interventional

The purpose of the Fresno Area Workforce Development Board FIRE program evaluation is to determine whether primary (i.e., behaviors) and secondary (i.e., attitudes) outcomes improve for participants after completing the Fresno FIRE program. Understanding the ways in which the Fresno FIRE program supports healthy parenting relationships and financial stability is important for those providing services to at-risk fathers.

NCT ID: NCT05244421 Recruiting - Fathers Clinical Trials

SAY San Diego Dad Corps FIRE Program Evaluation

Start date: April 1, 2021
Phase: N/A
Study type: Interventional

The purpose of the SAY San Diego Dad Corps FIRE program evaluation is to determine whether primary (i.e., behaviors) and secondary (i.e., attitudes) outcomes around parenting, co-parenting, employment, job readiness, and financial stability improve for participants after completing the SAY SDDC FIRE program.

NCT ID: NCT05256992 Recruiting - Fathers Clinical Trials

TYRO Champion Dads Project Study

Start date: April 1, 2021
Phase: N/A
Study type: Interventional

This impact evaluation aims to determine if the addition of 10 hours of domestic violence prevention programming is effective at improving outcomes among those program participants who are randomly assigned to the treatment group. Both study groups will receive standard TYRO Champion Dads services (the TYRO Dads and TYRO Core Communication evidence-based curricula, plus support services), but only the treatment group will be offered the additional Ray of Hope curriculum hours focused on mitigating risk factors related to domestic violence.

NCT ID: NCT05261802 Recruiting - Adults Clinical Trials

AVANCE-Houston FRAMEWorks Program Evaluation

Start date: April 1, 2021
Phase: N/A
Study type: Interventional

AVANCE-Houston seeks to understand whether a standard or compressed schedule format for delivering the Survival Skills for Healthy Families curriculum better meets the needs of low-income adults to improve skill retention and, ultimately, to promote better outcomes for healthy family relationships and economic stability.

NCT ID: NCT05263271 Recruiting - Clinical trials for Myelodysplastic Syndromes

Gentulizumab in Relapsed/Refractory Acute Myelogenous Leukemia or Myelodysplastic Syndrome

Start date: April 1, 2021
Phase: Phase 1
Study type: Interventional

Gentulizumab Injection is an anti-CD47 monoclonal antibody. As a member of the immunoglobulin superfamily, CD47 is expressed at low levels on many cells of the body, including hematopoietic cells (red blood cells, lymphocytes, platelets, etc.) and non-hematopoietic cells (placenta, liver and brain cells). It is overexpressed on many types of tumors. There is abundant supportive evidence that the expression of CD47 on tumor cells, though binding to SIRP on professional phagocytes, acts to prevent tumor cell phagocytosis, inhibit antigen cross-presentation, and block the production of pro-inflammatory molecules, thus promoting the development of a "cold" tumor microenvironment. Blocking CD47 can not only stimulate phagocytosis to cancer cells, but also promote macrophage recruitment towards neoplasm. At the same time, blocking CD47 can stimulate macrophages to secrete cytokines. These cytokines and chemokines can further recruit other immune cells to neoplasms. These newly recruited immune cells can provide a positive feedback and enhance the therapeutic response of blocking CD47. Therefore, the CD47/SIRPĪ± axis blocking appears to be a potential therapeutic target for neoplasm. Currently, no anti-CD47 antibody product has been granted marketing authorization for progressive hematological malignancies. Whereas Hu5F9-G4, a CD47 monoclonal antibody, is being tested in a series of ongoing clinical trials for AML, MDS, lymphomas and multiple solid tumors. The clinical research was designed based on non-clinical data and relevant experience of other CD47 monoclonal antibody. In this phase Ia study, "3 + 3" dose escalation method combined with rapid titration will be used to evaluate the dose limiting (DLT) toxicity of each dose group, evaluate the safety and tolerance of Gentulizumab in the treatment of patients with progressive hematological malignancies, and determine the maximum tolerated dose (MTD) and phase II recommended dose (RP2D); At the same time, the pharmacokinetics (PK), pharmacodynamics (PD), immunogenicity, preliminary efficacy and biomarkers of gentulizumab will be evaluated to provide sufficient basis for new drug application (NDA) guidance and further clinical use.

NCT ID: NCT05267236 Recruiting - Couples Clinical Trials

TYRO Couples Project Study

Start date: April 1, 2021
Phase: N/A
Study type: Interventional

This study uses an RCT design with repeated measures to test the impact of two different delivery formats for the TYRO Couples curriculum. Eligible study participants are males or females who are at least 18 years of age and within 9 months of release from incarceration. Incarcerated participants randomly assigned to the treatment group receive the TYRO Couples curriculum in-person, whereas those assigned to the comparison group experience an on-demand format. Study results that show no discernable differences in outcomes between groups will make it easier to serve more participants because service delivery formats can accommodate different life circumstances and preferences.